TNFRSF1A polymorphisms and MS Statistical signals transform into pathogenetic mechanisms
A genetic contribution to multiple sclerosis (MS) risk is now well-established, the strongest contributor being human leukocyte antigen (HLA). The quest for non-HLA MS susceptibility genes has reached a new level during the past 5 years through the application of genome-wide association studies. International consortia have designed studies with adequate power to identify susceptibility loci with substantially weaker effects than HLA. More than 50 such loci were recently confirmed or suggested in a large international analysis of 9,772 patients with MS and 17,376 controls. 1 A strikingly high proportion of the identified loci code for immune system components, in particular cytokine pathways, costimulation, and signal transduction, many of these linked with T-cell activation and T-helper-cell differentiation.
However, in many cases the associated genetic variants are of unclear functional significance. The story thus far has been a statistical story, enabled by the huge progress in genome-wide biotechnologies. With all these statistical signals in hand, the story remains unfinished until the causative variants are identified and their import to pathogenesis clarified.
One of the genes associated with MS risk is TNFRSF1A, 1,2 which is located on chromosome 12p13 and encodes TNF-R1, an important receptor for the proinflammatory cytokine, tumor necrosis factor (TNF)-a. TNF-a inhibitors induce relapses in MS and associated CNS demyelination in people with concurrent rheumatic disease. For instance, patients with MS treated with Lenercept, a soluble derivative of TNF receptor, which scavenges TNF-a thereby inhibiting its signaling, had more relapses as compared to placebo in a randomized controlled trial. 3 Treatment of people with rheumatic disease with TNF-a inhibitors, either blocking antibodies or soluble TNF receptor derivatives, causes demyelinating disorders in some patients, mostly but not exclusively in the CNS. 4 Although the exact mechanism is unknown, reduced T-cell apoptosis, a mechanism that normally eliminates autoreactive clones and maintains immune tolerance, is suspected to be involved.
Recently, Gregory et al. 5 reported that the TNFRSF1A single nucleotide polymorphism (SNP), rs1800693, is the common causal variant for MS risk. This risk allele (OR 1.12) is functional; it enhances skipping of one of the exons, changing the resulting mRNA and protein. The frameshift and premature stop codon in the mRNA generates a soluble protein (D6-TNF-R1) of 183 N-terminal amino acids followed by a novel sequence of 45 amino acids. The D6-TNF-R1 protein is capable of binding TNF-a 5 and may act as an endogenous TNF-a inhibitor akin to its drug counterparts that cause demyelinating disease.
In the current issue of Neurology ® , Comabella et al. 6 report the results of their evaluation of 2 MSassociated polymorphisms: rs1800693, the risk allele carried by 63% of their population, and rs4149584, a missense (R92Q) variant that was present in 7% of their cohort. The association of these 2 variants with age at onset and severity of MS was analyzed in 2,032 Spanish patients; in a subset of this cohort, functional consequences in mRNA and protein products was assessed.
There was no difference in MS patients' age at onset or severity by genotype for rs1800693, the high frequency intron-6 SNP, but carriers of the risk allele of rs4149584 (R92Q) had slightly lesser MS severity and younger age at onset than noncarriers. The rs4149584 R92Q substitution has been associated with the TNF receptor-associated periodic syndrome (TRAPS), an autoinflammatory disorder characterized by recurrent episodes of fever, myalgia, arthralgia, and other systemic complaints and with vulnerability to side effects of immunomodulatory therapies. 7 The authors, however, did not find such vulnerability in a retrospective analysis of the Spanish cohort, contrary to the previous report in German patients. 7 These contradictory results may reflect the uncertainty whether R92Q itself or a linked variant mediates these autoinflammatory reactions.
The functional consequences of the 2 variants were analyzed in a subset of approximately 140 patients. Considering rs1800693 first, the expression of the D6-TNF-R1 mRNA in peripheral blood mononuclear cells (encoding the truncated soluble D6-TNF-R1) was indeed associated with the risk allele. Unexpectedly, the ELISA method did not reveal increased soluble TNF-R1 in serum of carriers of the risk allele. Low levels of soluble TNF-R1 may be the explanation, since the authors report that D6-TNF-R1 mRNA expression was one-fifth of the full-length TNF-R1. Alternatively, rapid turnover of D6-TNF-R1 protein, or methodologic issues of the ELISA, may explain the lack of effect seen at the serum protein level. The rs4149584 (R92Q) risk allele was associated with higher serum levels of proteolytically cleaved soluble TNF-R1 but also with a higher overall TNF-R1 mRNA expression in peripheral blood mononuclear cells. Whether the underlying mechanism for rs4149584 is increased expression, increased proteolytic cleavage, or increased stability of the soluble protein remains to be elucidated.
The unifying theme is that both risk variants appear to increase the amount of soluble TNF-R1: rs1800693 by increased expression of D6-TNF-R1 (detected by mRNA analysis) and rs4149584 by increased serum concentration of soluble TNF-R1 (detected by ELISA). These new data on rs1800693 confirm the results of Gregory et al. 5 Together these studies provide compelling evidence that the risk allele induces D6-TNF-R1 in a dose-dependent manner. The risk allele only partially induced the expression of D6-TNF-R1 mRNA, which is a novel finding.
The TNFRSF1A gene case is a clear indication that the field of MS genetics is moving beyond statistics to biology, and perhaps closer to the "end game." By contrast to the high-throughput search to identify MS-associated genetic variants, the biological work is slow, and limited by our understanding of the precise targets of interest (e.g., which immune cell population is most affected by a genetic variant), and confounded by limited sensitivity of biological assays due to the noise produced by irrelevant cell populations. Expression of genes varies over time and stimulated expression may not reflect the events pertinent to MS. The road ahead is likely to be slow going and requires immunologic and cell biological expertise but undoubtedly will bring our understanding of the mechanisms and treatment strategies of MS to a new level.
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